Thrivent Financial for Lutherans Trims Position in CareDx, Inc (NASDAQ:CDNA)

Thrivent Financial for Lutherans reduced its holdings in CareDx, Inc (NASDAQ:CDNA) by 28.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 57,939 shares of the company’s stock after selling 23,392 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.11% of CareDx worth $1,240,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in CDNA. Royce & Associates LP increased its stake in shares of CareDx by 23.1% during the 4th quarter. Royce & Associates LP now owns 484,286 shares of the company’s stock valued at $10,369,000 after acquiring an additional 91,000 shares during the last quarter. Swiss National Bank increased its position in CareDx by 1.9% during the fourth quarter. Swiss National Bank now owns 98,600 shares of the company’s stock worth $2,111,000 after purchasing an additional 1,800 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in CareDx by 25.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 875,197 shares of the company’s stock worth $18,738,000 after purchasing an additional 178,304 shares during the period. AlphaQuest LLC boosted its holdings in shares of CareDx by 131.8% in the 4th quarter. AlphaQuest LLC now owns 13,004 shares of the company’s stock valued at $278,000 after purchasing an additional 7,393 shares during the last quarter. Finally, Edgestream Partners L.P. purchased a new stake in shares of CareDx during the 4th quarter valued at $728,000.

CareDx Stock Down 1.2 %

NASDAQ CDNA opened at $17.75 on Tuesday. The stock has a market cap of $983.81 million, a PE ratio of -6.57 and a beta of 1.95. The business has a 50 day moving average price of $21.32 and a two-hundred day moving average price of $23.52. CareDx, Inc has a fifty-two week low of $7.42 and a fifty-two week high of $34.84.

CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The business had revenue of $86.58 million during the quarter, compared to analyst estimates of $84.56 million. Sell-side analysts anticipate that CareDx, Inc will post -0.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CDNA has been the topic of a number of research analyst reports. Stephens reiterated an “overweight” rating and issued a $40.00 target price on shares of CareDx in a report on Thursday, February 27th. HC Wainwright reduced their price objective on CareDx from $26.00 to $25.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Wells Fargo & Company raised shares of CareDx from an “underweight” rating to an “equal weight” rating and dropped their target price for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. Finally, StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research report on Wednesday, February 26th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $31.83.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.